Patients with multiple sclerosis treated with natalizumab may rarely develop progressive multifocal leukoencephalopathy (PML), a serious and often fatal disease caused by infection with JC virus. The ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...
Please provide your email address to receive an email when new articles are posted on . Researchers performed genetic analyses of 336 cases of those with PML, 94 of whom were patients with MS. Four ...
Patients with multiple sclerosis (MS) should be evaluated before, and regularly during, treatment with fingolimod (Gilenya, Novartis) to identify signs and symptoms possibly linked to progressive ...
Biogen Idec Inc. and Elan Corp. plc reported two new cases of PML — though not much else, to the chagrin of investors and analysts — linked to multiple sclerosis therapy Tysabri (natalizumab), ...
Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...
The FDA has approved the first biosimilar to treat multiple sclerosis, Sandoz's injection treatment natalizumab-sztn (Tyruko). Sandoz's injection treatment natalizumab-sztn (Tyruko) has been approved ...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results